Women's Health Market Size to Reach USD 106.6 Billion By 2035

The Global Women’s Health Market was worth USD 59.3 billion in 2025 and is expected to reach USD 106.6 billion by 2035, growing at a CAGR of 6.8% from 2025 to 2035. Based on this growth rate, the market is estimated to reach around USD 64.0 billion in 2026. North America held the largest regional share of 44.6% in 2025, valued at USD 26.4 billion, and is expected to grow at a CAGR of 6.5%, supported by advanced healthcare access, strong awareness of reproductive health, higher use of prescription therapies, and rising demand for preventive women’s care.

The Women’s Health Market includes products, services, diagnostics, drugs, devices, and digital health solutions focused on female health needs across different life stages. These include contraceptives, hormonal therapies, fertility care, pregnancy and maternal health solutions, menopause treatments, osteoporosis care, gynecological disease management, breast health, cervical cancer screening, and wellness-focused healthcare services. Demand is supported by continued use of reproductive health products, as CDC data showed that 54.3% of U.S. females aged 15 to 49 were using a contraceptive method in 2022 to 2023.

The market outlook remains positive as healthcare systems place greater focus on early diagnosis, preventive care, fertility planning, maternal health, and age-related women’s health conditions. Growth can be attributed to rising awareness of cervical cancer prevention, breast health, menopause care, hormonal treatment, and digital health platforms for women. The need for improved care remains strong, as WHO reported about 260,000 maternal deaths worldwide in 2023, while cervical cancer continues to create a major disease burden among women globally. These factors are expected to support long-term demand across pharmaceuticals, diagnostics, devices, telehealth, and specialty women’s health clinics.

Key Market Insights

• Contraceptives led the application segment with 35.5% share, supported by rising awareness of reproductive health, wider access to family planning products, and increasing demand for effective birth control solutions.

• Hormonal therapies accounted for 42.7% share by drug class, driven by their strong use in contraception, menopause management, menstrual disorders, fertility support, and hormone-related treatments.

• Women below 50 years held 49.8% share by age group, supported by higher demand for reproductive care, menstrual health products, fertility solutions, pregnancy-related care, and preventive health services.

• Retail pharmacies captured 46.1% share by distribution channel, driven by easy product access, prescription availability, OTC women’s health products, and strong consumer preference for nearby pharmacy purchases.

• North America led the women’s health market with 44.6% share, valued at USD 26.4 billion in 2025, and is projected to grow at a CAGR of 6.5%, supported by advanced healthcare access, strong awareness of women’s health conditions, and wider adoption of preventive care.

Application Insights

Contraceptives led the application segment with 35.5% share. The segment remained ahead because contraception is a core part of women’s healthcare, covering oral pills, implants, injectables, intrauterine devices, emergency contraception, and barrier methods. The demand for contraceptives is being supported by rising focus on reproductive planning, birth spacing, menstrual cycle management, and access to family planning services.

UNFPA’s 2025 family planning update stated that 259 million women who want to avoid pregnancy are not able to use safe and effective modern contraceptive methods, showing a major access gap that continues to support product and service demand. The segment is also supported by policy-level attention to reproductive health. In 2025, UNFPA highlighted that contraceptive access helps prevent unintended pregnancies, unsafe abortions, and maternal deaths, which keeps contraception at the center of women’s health programs.

Drug Class Insights

Hormonal therapies led the drug class segment with 42.7% share. The segment remained dominant because hormonal treatments are used across contraception, menopause care, menstrual disorders, fertility support, and hormone-related gynecological conditions. In 2026, the FDA approved labeling changes for menopausal hormone therapy products.

The agency removed certain risk statements from boxed warnings for selected products and noted approved uses for moderate-to-severe hot flashes, vaginal dryness and discomfort, and prevention of bone loss. This update is important for the hormonal therapies segment because it may improve confidence among patients and healthcare professionals. It also supports more informed treatment discussions for menopause symptoms, which remain a major part of women’s midlife healthcare needs.

Age Group Insights

Below 50 years accounted for 49.8% share. This age group remained a key demand base because women below 50 commonly require contraception, fertility care, pregnancy-related support, menstrual health management, and preventive gynecological services. The segment is supported by the continued importance of reproductive-age care. UNFPA’s 2025 update noted that family planning includes contraceptives, infertility care, fertility-awareness methods, and information for people who want to become pregnant, which directly supports demand among younger and mid-age women.

Women below 50 are also more likely to use repeated healthcare services for conditions such as endometriosis, polycystic ovary syndrome, abnormal uterine bleeding, cervical health concerns, and fertility-related issues. This makes the age group important for medicines, diagnostics, digital health tools, pharmacy access, and specialist consultations.

Distribution Channel Insights

Retail pharmacy led the distribution channel segment with 46.1% share. The segment remained strong because many women’s health products are repeat-use or prescription-led, including contraceptives, hormonal therapies, prenatal products, pain relief medicines, and treatment products for gynecological conditions. Retail pharmacies are important because they provide medicine access close to communities.

In 2026, NACDS stated that chain pharmacies operate approximately 32,000 pharmacy locations in the U.S., which shows the wide reach of pharmacy-based access for patients. The channel is also supported by the need for refills, pharmacist guidance, affordability, and convenient access. For women managing long-term or recurring health needs, retail pharmacies remain a practical point of care between doctor visits.

Regional Insights

North America dominated the regional segment with 44.6% share, supported by strong healthcare access, higher awareness of women’s health conditions, and broad prescription-based treatment use. The region is being supported by active policy and regulatory attention.

How Big is the North America Women's Health Market Size?

The North America Women’s Health Market is a large and well-established market, supported by high healthcare spending, strong awareness of preventive care, and wider access to advanced treatment options. The North America Women’s Health Market was valued at USD 26.4 billion in 2025 and is estimated to reach USD 28.1 billion in 2026. The market is expected to grow to approximately USD 49.6 billion by 2035, registering a CAGR of 6.5% from 2025 to 2035.

In 2026, the U.S. Office on Women’s Health used the theme "Prevention, Innovation, and Impact: A New Era in Women’s Health" with focus areas including hormone therapy, heart health, bone and muscle health, and better health outcomes. North America also benefits from stronger research, pharmacy infrastructure, and regulatory activity in women’s health. The FDA’s 2026 hormone therapy labeling changes and the large U.S. retail pharmacy network continue to support access to women’s health medicines and related care services.

Segment Covered in the Report

By Application

• Contraceptives

• Osteoporosis

• Menopause

• Infertility

• Others

By Drug Class

• Hormonal Therapies

• Bone Health Agents

• Pain and Symptom Management

• Others

By Age Group

• Below 50 Years

• 50 Years and Above

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Drivers Impact Analysis

The Women’s Health Market is driven by rising awareness of reproductive health, higher diagnosis of hormonal disorders, increasing use of prescription therapies, growing preventive care, and stronger demand for contraception, fertility support, menopause care, and gynecological treatments. Women are seeking earlier diagnosis and better treatment access across every life stage.

North America leads the market because of advanced healthcare infrastructure, strong access to prescription drugs, higher screening rates, and better awareness of women-focused health conditions. The region’s 6.5% CAGR shows steady demand for reproductive health, hormonal therapies, preventive care, and chronic condition management.

Restraints Impact Analysis

The market faces restraints from high treatment cost, unequal healthcare access, social stigma around reproductive health, and limited awareness in underserved regions. Many women still delay care due to affordability, privacy concerns, or lack of specialized providers.

Another restraint is regulatory sensitivity around hormonal drugs, fertility products, and reproductive health therapies. Safety monitoring, prescription controls, and policy differences can slow product adoption across different countries.

Opportunities Impact Analysis

Opportunities are strong in contraceptives, hormonal therapies, fertility treatment, menopause care, osteoporosis management, gynecological drugs, digital women’s health platforms, and preventive screening solutions. These areas benefit from rising healthcare awareness and growing demand for personalized care.

Higher-value opportunities are also emerging in FemTech, telehealth, at-home diagnostics, digital fertility tracking, and prescription-based care models. Companies that combine clinical credibility with easier access and patient education can capture stronger long-term growth.

Challenges Impact Analysis

The main challenge is delivering accessible women’s healthcare across income groups, age groups, and geographies. Advanced products and therapies are available in developed markets, but affordability and availability remain weaker in many emerging regions.

Another challenge is building trust and improving patient education. Women’s health conditions such as endometriosis, PCOS, menopause symptoms, infertility, and reproductive disorders are often underdiagnosed or discussed late, which affects treatment timing and outcomes.

Go-to-Market and Sales Economics

According to Globe Market Research, the Women’s Health Market go-to-market approach should focus on lifecycle-based care, including contraception, fertility, pregnancy, menopause, gynecological disorders, breast health, sexual health, and preventive screening. Demand is being supported by rising awareness, wider employer benefits, new drug approvals, and better diagnostic access. In 2026, Hologic reported that about 1.5 billion adult women worldwide had missed essential health screenings in the past year, highlighting a major opportunity for diagnostics and preventive care providers.

Sales economics are shifting toward integrated care models rather than single-product selling. Pharmaceutical companies, diagnostic firms, fertility clinics, digital platforms and employer benefit providers are expanding across multiple women’s health needs to improve retention and lifetime value. Hologic reported USD 1,047.8 million in Q1 fiscal 2026 revenue, with Breast Health revenue of USD 375.9 million and Surgical revenue of USD 180.8 million, showing the commercial strength of diagnostics, imaging and gynecological procedure technologies.

The strongest commercial route is expected to come from therapies and services that address underdiagnosed or underserved conditions. Menopause is becoming a high-growth care area after the FDA approved Bayer’s Lynkuet in 2025 as a non-hormonal treatment for moderate to severe hot flashes linked to menopause. Reuters reported that the drug was priced at a wholesale level of USD 625 per month, while Bayer is targeting at least USD 1 billion in peak annual sales, showing how unmet needs in menopause care are becoming commercially important.

Revenue Potential Analysis

Revenue Landscape Across

Revenue potential is spread across contraceptives, fertility treatments, menopause therapies, maternal health, breast imaging, gynecological surgery, STI testing, pelvic health, digital health apps, employer fertility benefits and preventive screening programs. Fertility and reproductive care remain important because the U.S. provisional number of births declined to 3,606,400 in 2025, while the general fertility rate stood at 53.1 births per 1,000 women aged 15 to 44. This supports demand for fertility planning, assisted reproduction, pregnancy support and reproductive health services.

Diagnostics and preventive care represent one of the largest revenue channels because screening gaps remain wide across both developed and emerging healthcare systems. The Hologic Global Women’s Health Index Year 5 report covered women’s health experiences across 144 countries and territories, showing that progress in preventive care remains uneven. This creates revenue opportunities for mammography systems, cervical cancer screening, STI tests, diabetes screening, hypertension checks and digital follow-up platforms.

Women’s health innovation funding is also improving the revenue base for digital and AI-enabled care. SVB’s 2026 women’s health investment report stated that women’s health companies attracted USD 2 billion in investment in 2025, while AI-enabled women’s health companies had a median pre-money valuation of USD 35 million. This supports commercialization of hormone tracking, cycle monitoring, virtual care, menopause support, fertility navigation and personalized care platforms.

Financial Impact

The financial impact of the Women’s Health Market is linked to early diagnosis, better treatment access, reduced care gaps and stronger long-term patient engagement. Maternal health remains a major public health and commercial care priority, as WHO reported that about 260,000 women died during and after pregnancy and childbirth in 2023, with around 92% of maternal deaths occurring in low and lower-middle-income countries. This supports demand for prenatal care, risk monitoring, obstetric diagnostics, postpartum services and digital maternal health tools.

Company performance shows that women’s health revenue can be attractive, but product concentration and channel changes can create short-term pressure. Organon reported that its Women’s Health revenue declined 16% as reported in Q1 2026, mainly reflecting challenges in key portfolio areas. This highlights the need for diversified portfolios across contraception, fertility, menopause and biosimilar-linked women’s care rather than dependence on a few major products.

Recent Developments

Market News

• In January 2026, Organon received U.S. FDA approval to extend NEXPLANON use from three years to up to five years, supported by trial data showing no pregnancies during years four and five and no new safety findings.

• In January 2026, Maven Clinic launched its Clinical Research Institute to build and share evidence on digital care for women and families.

• In February 2026, the U.S. FDA approved labeling changes for six menopausal hormone therapy products, removing boxed warning risk statements related to cardiovascular disease, breast cancer, and probable dementia.

• In May 2026, Maven Clinic expanded its direct-to-consumer virtual care platform across the U.S., adding access to more than 30 specialties, hormone care, and GLP-1 care designed for women.

• In June 2026, Xella Health launched an AI-powered women’s health diagnostics platform designed to detect more than 130 often-misdiagnosed women’s health conditions.

Acquisitions

• In March 2026, Gedeon Richter acquired Celmatix’s women’s health discovery portfolio, adding programs across infertility, endometriosis, and ovarian aging.

• In April 2026, Sun Pharma signed a definitive agreement to acquire Organon in an all-cash deal valued at USD 11.75 billion, strengthening its global position in women’s health, biosimilars, and specialty medicines.

• In April 2026, Noom acquired Tailor Made Compounding to expand beyond weight health into preventive care, healthy aging, and hormonal health offerings.

• In June 2026, Elation Health acquired Aster, an AI-native EHR focused on women’s health, to expand agentic AI capabilities in primary care workflows.

• In June 2026, WPS acquired Mavida Health to expand digital mental health care and community support for women and families navigating reproductive life stages.

Funding

• In January 2026, Pinky Promise raised USD 1 million in pre-seed funding to expand its AI-enabled women’s health digital clinic in India.

• In February 2026, Midi Health raised USD 100 million in Series D funding at a valuation above USD 1 billion to scale its perimenopause and menopause care platform.

• In March 2026, Malama Health raised USD 9.2 million to scale doula-led maternal care for Medicaid populations.

• In April 2026, Flora Fertility raised USD 5 million in seed funding to build individually owned fertility insurance that is not tied to employer benefits.

• In April 2026, Future Fertility raised USD 4.1 million in Series A funding to scale AI-powered egg quality assessment for IVF and egg freezing.

• In June 2026, Clair Health raised USD 11.6 million in seed funding to build a noninvasive wearable designed to track women’s hormones.